T-cell-specific humanized single fragment antibody delivery vehicle

Patent metadata

Field	Value
Publication number	US-9683042-B2
Application number	US-201314654273-A
Country	US
Kind code	B2
Filing date	Mar 5, 2013
Priority date	Dec 20, 2012
Publication date	Jun 20, 2017
Grant date	Jun 20, 2017

Abstract

The present invention relates to a humanized scFv delivery vehicle targeted to be human T-cell specific, and provides: a humanized scFv which comprises a heavy-chain variable region (VH) consisting of a polypeptide comprising an amino acid sequence given by sequence number 32 and comprises a light-chain variable region (VL) consisting of a polypeptide comprising an amino acid sequence given by sequence number 34; and a T-cell-specific drug or marker delivery vehicle comprising the humanized scFv. The humanized scFv of the present invention has minimalised antigenicity and has an effect which does not give rise to an immune reaction even when used in the human body, and thus can advantageously be used as a delivery vehicle for specifically delivering a target substance such as a siRNA gene or an immune reaction regulating protein to T-cells.

First claim

The invention claimed is:

1. A human CD7-specific humanized scFv comprising a heavy chain variable region (V H ) composed of a polypeptide including the amino acid sequence represented by SEQ ID NO: 32, and a light chain variable region (V L ) composed of a polypeptide including the amino acid sequence represented by SEQ ID NO: 34.

2. The humanized scFv of claim 1 , wherein the humanized scFv targets specifically to human CD7-expressing T cells.

3. The humanized scFv of claim 1 , wherein the humanized scFv is composed of a polypeptide including the amino acid sequence represented by SEQ ID NO: 36.

4. An expression vector comprising a nucleotide sequence coding the humanized scFv of claim 1 .

5. The expression vector of claim 4 , wherein the expression vector includes the nucleotide sequence represented by SEQ ID NO: 37.

6. A carrier for delivering a T-cell activity regulator or a label specifically to T cells by targeting the T cells, the carrier comprising the humanized scFv of claim 1 .

7. A composition containing a label fused to the N-terminal or C-terminal of the humanized scFv of claim 1 .

8. A pharmaceutical composition for treating T cell-mediated diseases, the pharmaceutical composition containing a T-cell activity regulator fused to the N-terminal or C-terminal of the humanized scFv of claim 1 , wherein said T-cell mediated diseases are selected from the group consisting of acquired immunodeficiency syndrome (AIDS), graft rejection, graft-versus-host diseases, unwanted delayed type of hypersensitivity reactions, T cell-mediated pulmonary diseases, autoimmune diseases, multiple sclerosis, neuritis, polymyositis, psoriasis, vitiligo, Siogren's syndrome, rheumatoid arthritis, type 1 diabetes, autoimmune pancreatitis inflammator bowel disease, Crohn's disease, ulcerative colitis, celiac disease, glomerulonephritis, scleroderma, sarcoidosis, autoimmune thyroid disease, Hashimoto's thyroiditis, Graves' disease, myasthenia pravis, Addison's disease, autoimmune uveoretinitis, pemphigus vulgaris, primary biliary cirrhosis, pernicious anemia, and systemic lupus erythematosus.

9. The pharmaceutical composition of claim 8 , wherein the T-cell activity regulator is a T-cell activity inhibitor or a T-cell activity enhancer.

10. The pharmaceutical composition of claim 8 , wherein the T-cell activity regulator is small interfering RAN (siRNA).

11. A method for treating T cell-mediated diseases, the method comprising administering to a subject a composition containing a pharmaceutically effective amount of a T-cell activity regulator fused on the N-terminal or C-terminal of the humanized scFv of claim 1 , wherein said T-cell mediated diseases are selected from the group consisting of acquired immunodeficiency syndrome (AIDS), graft rejection, graft- versus-host diseases, unwanted delayed type of hypersensitivity reactions. T cell-mediated pulmonary diseases, autoimmune diseases, multiple sclerosis, neuritis, polymyositis, psoriasis, vitiligo, Sjogren's syndrome, rheumatoid arthritis, type 1 diabetes, autoimmune pancreatitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, celiac disease, glomerulonephritis, scleroderma, sarcoldosis, autoimmune thyroid disease, Hashimoto's thyroiditis, Graves' disease, myasthenia gravis, Addison's disease, autoimmune uveoretinitis, pemphigus vulgaris, primary biliary cirrhosis, pernicious anemia, and systemic lupus erythematosus.

12. The method of claim 11 , wherein the T-cell activity regulator is a T-cell activity inhibitor or T-cell activity enhancer.

13. The method of claim 11 , wherein the T-cell activity regulator is small interfering RAN (siRNA).

Assignees

• Industry-Univ Coop Found Hanyang Univ
• Industry-Univ Coop Found Hanyang Univ

Inventors

• Lee Sang Kyung
• Hong Hyo Jeong
• Kumar Priti

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• C12N2310/3513

  Protein; Peptide · CPC title

• A61K47/484

  Human Necessities · mapped topic

• C07K16/2803 Primary

  against the immunoglobulin superfamily · CPC title

• C12N15/111

  General methods applicable to biologically active non-coding nucleic acids · CPC title